Biotechnology
Atyr Pharma To Present At Upcoming Investor Conferences
Share
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025.
Details of the conferences appear below:
Conference: RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 21, 2025
Time: 11:00am EDT
Location: New York, NY
Format: Fireside Chat
Conference: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways
Date: Tuesday, May 27, 2025
Time: 2:00pm EDT
Location: Virtual
Format: Fireside Chat
Conference: Jefferies Global Healthcare Conference
Date: Thursday, June 5, 2025
Time: 2:00pm EDT
Location: New York, NY
Format: Fireside Chat
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: | |
| Ashlee Dunston | |
| Sr. Director, Investor Relations and Public Affairs | |
| adunston@atyrpharma.com | |
Frequently Asked Questions
What is aTyr Pharma?
aTyr Pharma is a clinical-stage biotechnology company developing first-in-class medicines from its tRNA synthetase platform, targeting fibrosis and inflammation.
What is efzofitimod?
Efzofitimod is aTyr's lead therapeutic candidate, a biologic immunomodulator in clinical development for interstitial lung disease.
Where can I find more information about aTyr Pharma?
Visit aTyr Pharma's website at www.atyrpharma.com for more information.
First published on Tue, May 20, 2025
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending GlobeNewswire
Nordvpn Adds AI Voice Detector To Its Chrome Extension
Wizeline Names Ins Casares As Chief Executive Officer
Bizclik Media Launches AI LIVE London 2026 To Unite Global Leaders Driving Enterprise AI Transformation
Geekplus Partners With Mindugar To Accelerate Warehouse Automation Adoption Across Latin America
Heatgov Project Begins Public Rollout Of Infrastructure-Focused Blockchain Initiative
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion